脑转移瘤的分次立体定向放疗:一项回顾性研究的结果
该回顾性研究纳入2017年1月至2021年12月在德国雷根斯堡大学医院接受6次5 Gy低分次立体定向放疗的73例脑转移瘤患者(共103个病灶),评估无局部进展生存、总生存和远处脑进展无生存;中位总生存为17.4个月,6次5 Gy方案似乎有效且局部控制可接受,但黑色素瘤和肾细胞癌的局部控制似乎更差。
要点
- 6次5 Gy低分次立体定向放疗的中位总生存为17.4个月(95%CI 9.9, 24.9)。
- 平均无局部进展生存为38.1个月(95%CI 31.4, 44.9),中位未达到。
- 5个脑转移灶(4.8%)发生脑放射性坏死。
核心结论
- 6次5 Gy的分次立体定向放疗似乎是一种有效治疗,对脑转移瘤患者具有可接受的局部控制,尽管黑色素瘤和肾细胞癌与其他癌症相比似乎局部控制更差。
研究设计与样本
- 回顾性研究纳入2017年1月至2021年12月在德国雷根斯堡大学医院接受6次5 Gy低分次立体定向放疗的73例患者共103个脑转移灶。
- 研究评估既往未接受脑放疗患者的无局部进展生存、总生存和远处脑进展无生存,并报告缓解率和脑放射性坏死。
- 采用Cox比例风险模型评估总生存和无局部进展生存的预后因素。
主要发现
- 患者中位年龄61.0岁(四分位距51.0, 67.5),最常见肿瘤类型为恶性黑色素瘤(34.2%)和非小细胞肺癌腺癌(26.0%)。
- 中位肿瘤大体体积为0.9 cm³(四分位距0.4, 3.6),所有患者中位随访时间36.3个月(95%CI 29.1, 43.4)。
- 中位总生存为17.4个月(95%CI 9.9, 24.9),6、12、18、24和30个月总生存率分别为81.9%、59.1%、49.0%、41.3%和37.2%。
- 平均无局部进展生存为38.1个月(95%CI 31.4, 44.9),中位无局部进展生存未达到,6、12、18、24和30个月无局部进展生存率分别为78.9%、68.7%、64.3%、61.6%和58.7%。
- 所有患者中位远处脑进展无生存为7.7个月(95%CI 6.1, 9.3),6、12、18、24和30个月远处脑进展无生存率分别为62.1%、36.3%、31.1%、24.8%和21.7%,5个脑转移灶(4.8%)发生脑放射性坏死。
关键数值与推荐
- 多因素分析中,脑转移灶数量对无局部进展生存有负面影响。
- 与其他癌症相比,非黑色素瘤和非肾细胞癌与更高的无局部进展生存机会相关。
- 与肿瘤大体体积≤1.5 cm³相比,肿瘤大体体积>1.5 cm³意味着更高的死亡风险,卡氏功能状态评分可预测总生存。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Lasting local control of brain metastases following stereotactic radiotherapy is becoming increasingly relevant since systemic treatment constantly improves the prognosis of patients with extracranial metastases. METHODS: 73 patients with 103 brain metastases received hypofractionated stereotactic radiotherapy (FSRT) in 6 fractions of 5 Gy between January 2017 and December 2021 at the University Hospital Regensburg, Germany. The study retrospectively evaluated local progression free survival (LPFS), overall survival (OS) and distant brain progression free survival (DPFS) of patients without prior radiotherapy of the brain. Response rate and brain radiation necrosis were reported. Cox proportional hazard models evaluated prognostic factors of OS and LPFS. RESULTS: The median patient age was 61.0 years (Interquartile range, IQR 51.0, 67.5). The most common tumor types were malignant melanoma (34.2%) and non-small cell lung adenocarcinoma (26.0%). The median gross tumor volume (GTV) was 0.9 cm³ (IQR 0.4, 3.6). The median follow-up time of all patients was 36.3 months (95%CI 29.1, 43.4). The median OS was 17.4 months (95%CI 9.9, 24.9). Overall survival rates at 6-, 12-, 18-, 24-, and 30 months were 81.9%, 59.1%, 49.0%, 41.3%, and 37.2%, retrospectively. The mean LPFS was 38.1 months (95%CI 31.4, 44.9), while the median LPFS has not been reached. LPFS rates at 6-, 12-, 18-, 24- and 30 months were 78.9%, 68.7%, 64.3%, 61.6% and 58.7%, retrospectively. Median DPFS of all patients was 7.7 months (95%CI 6.1, 9.3). Six, 12-, 18-, 24- and 30 months DPFS rates were 62.1%, 36.3%, 31.1%, 24.8% and 21.7%. Five brain metastases (4.8%) developed brain radiation necrosis. In multivariate analysis, the number of brain metastases negatively affected LPFS. Non-melanoma and non-renal cell cancer was associated with a higher chance of LPFS in comparison to other cancer. A GTV > 1.5 cm³ translated into a higher risk of death compared to a GTV ≤ 1.5 cm³ and Karnofsky performance score was predictive of OS. CONCLUSIONS: FSRT in 6 fractions of 5 Gy seems to be an effective treatment with an acceptable local control for patients with brain metastases although melanoma and renal cell cancer seem to have a worse local control in comparison to other cancer. TRIAL REGISTRATION: This study is retrospectively registered.
引用
- Gruber I, Stark P, Weidner K, et al. Fractionated stereotactic radiotherapy of brain metastases: results of a retrospective study. Radiat Oncol. 2023. PMID: 37217924. doi:10.1186/s13014-023-02277-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。